CONTACT US   |  (864) 397-5101

Cannabis and the oral microbiome: Exploring their impacts on the brain

Human tooth with Microscopic bacteria and viruses , Germs. 3d illustration.

Inspiration strikes when you least expect it. For Wei Jiang, M.D., a professor of Microbiology and Immunology at MUSC, inspiration came in 2018 on a smoke-filled boat tour around Amsterdam during an international conference.

“Everyone was smoking cannabis except me,” said Jiang. “I was studying the microbiome at the time, so after talking to them, I figured out their oral health was affected by smoking and wanted to understand this further.”

In the years since, Jiang has focused her research on how smoking cannabis alters the oral microbiome, or the community of bacteria that live in the mouth. The South Carolina Clinical and Translational Research Institute provided pilot funding for Jiang’s research.

Now, with $3.7 million in recent funding from the National Institute on Drug Abuse (NIDA), Jiang and her collaborator Sylvia Fitting, Ph.D., from the University of North Carolina at Chapel Hill, will dive deeper into the effects of cannabis-caused changes to the oral microbiome and their impacts on neurological disease.

“This will be the first study to investigate the cannabis-altered oral microbiome and its effects on the brain,” said Jiang.

Cannabis is the most widely used drug in the U.S. and can have positive mental effects, such as reducing anxiety. However, long-term use can lead to impaired memory, learning and motor skills, said Jiang. Smoke also contains harmful compounds from combustion that affect oral health.

Changes in oral bacteria have been linked to cardiovascular diseases, preterm birth and even Alzheimer’s disease. Unnatural changes in the oral microbiome, known as dysbiosis, can allow harmful bacteria to thrive in the mouth and even enter the bloodstream, damaging other organs, such as the brain.

Jiang and her collaborators showed in a December 2021 EBioMedicine study that frequent cannabis use alters the oral microbiome. They found unusually high levels of the bacterium Actinomyces meyeri, A. meyeri, in frequent cannabis users but not in tobacco or cocaine users.

“In general, the amount of A. meyeri should be very low in a healthy oral microbiome,” said Jiang.

Mice orally exposed to A. meyeri for six months showed increased inflammation and more amyloid-beta proteins in their brains. These proteins are thought to be linked to long-term memory loss and Alzheimer’s disease.

“After we saw these changes in mice given this bacterium, we became very intrigued by what was happening in their brains,” said Jiang.

The new grant funding will enable the team to explore the mechanisms underlying the link between high levels of A. meyeri in the oral microbiome of frequent cannabis users and neurological disease.

“Psychological dependency on a drug can have harmful neurological effects, but we don’t know what is driving these effects in heavy cannabis users,” said Jiang. “We know that oral health affects your mental health. However, we don’t know exactly what role the microbiome plays.”

Although Jiang’s earlier work showed that the cannabis-altered oral microbiome played a role in neurological changes, it did not specifically look at what component of cannabis caused those changes. Cannabis contains both psychoactive (THC) and non-psychoactive (CBD) components, which interact with the brain and nervous system in different ways.

“Now, we want to identify the specific effects of THC and CBD on oral microbiome dysbiosis and mental health,” said Jiang.

Jiang plans to expose mice to different levels of THC and CBD to determine their effects on levels of A. meyeri.

“We think that long-term exposure to THC, but not CBD, will increase levels of A. meyeri in saliva and lead to harmful neurological effects in mice,” said Jiang.

In the new study, Jiang will also move beyond mouse models to humans with cannabis use disorder to see how changes in their oral microbiomes affect memory.

“We expect memory-related deficits to be associated with greater levels of A. meyeri in frequent cannabis users compared with nonusers,” said Jiang.

Jiang’s research highlights the importance of oral health and its complex relationship with other diseases.

“Anyone using cannabis frequently should pay particular attention to their oral hygiene,” said Jiang.

With support from the NIDA grant, Jiang plans to lay a foundation for developing therapeutics that target the oral microbiome in frequent cannabis users with neurological disorders.

“If our hypothesis is correct, a therapeutic strategy targeting A. meyeri could reduce irregularities in brain function in frequent cannabis users,” said Jiang. “In the future, it may also be useful to screen for certain bacteria as biomarkers of different diseases that affect the brain, such as Alzheimer’s disease.”


Luo Z, Fitting S, Robinson C, et al. Chronic cannabis smoking-enriched oral pathobiont drives behavioral changes, macrophage infiltration, and increases β-amyloid protein production in the brain. EBioMedicine. 2021 Dec;74:103701. doi: 10.1016/j.ebiom.2021.103701. Epub 2021 Nov 23. PMID: 34826801; PMCID: PMC862658

About the Author

Ryan Barrs
Ryan Barrs is a Ph.D. candidate in the Clemson-MUSC Joint Bioengineering Program and a College of Graduate Studies science communications intern. His research in the lab of Dr. Ying Mei focuses on cardiovascular tissue engineering. He is supported by an NIH F31 predoctoral fellowship.

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.